Long-Term Follow-up of Subjects Who Were Treated With ST-920

Part of paid clinical trials in Irvine, California.

Sponsor
Sangamo Therapeutics
Study ID
NCT05039866
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ST-920 — BIOLOGICAL
    No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.

Study Details

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Key Dates

First listed
Sep 10, 2021
Start date
Aug 16, 2021
Status verified
May 2025
Primary completion
Mar 31, 2029
Completion
Mar 31, 2039

Study Design

Enrollment
48 participants (estimated)

Arms

  • Arm: Subjects who received ST-920
    Subjects who received ST-920 in a separate parent trial

Primary Outcome Measure

To evaluate long-term safety of ST-920 [ Time Frame: 4 years ]

Locations (8)

FacilityCityStateZIPSite coordinators
University of California, IrvineIrvineCalifornia92697-
University of South FloridaTampaFlorida33620-
Emory University School of MedicineAtlantaGeorgia30322-
University of Iowa Hospital and ClinicsIowa CityIowa52242-
University of Minnesota Medical CenterMinneapolisMinnesota55455-
Mt. Sinai HospitalNew YorkNew York10029-
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229-
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)FairfaxVirginia22030-

Find similar trials in Irvine, CA

By research site
University of California, Irvine· Irvine, CAUniversity of South Florida· Tampa, FLEmory University School of Medicine· Atlanta, GAUniversity of Iowa Hospital and Clinics· Iowa City, IAUniversity of Minnesota Medical Center· Minneapolis, MNMt. Sinai Hospital· New York, NY

Related Studies